Reframing Project ECHO for Sickle Cell Disease as Sustainable Clinical Decision Infrastructure: A Tumor-Board–Analogous Care Model
Kenneth A RivlinAbstract
Background
Adult sickle cell disease (SCD) care faces persistent workforce shortages; a challenge commonly framed as a need to expand the SCD workforce through training models that enable non-specialist clinicians to practice independently. Project ECHO is frequently described as a workforce development strategy focused on training non-specialists; however, evidence supporting autonomy-based workforce development for this rare, high-complexity disease remains limited. In contrast, SCD clinical guidelines emphasize multidisciplinary expertise, shared decision-making, and clearly defined processes for involving additional specialty expertise as clinical complexity increases—features characteristic of tumor-board–based care models used in oncology. In these settings, workforce sufficiency is achieved through durable systems of shared clinical expertise rather than through time-limited educational interventions alone. We examined whether Project ECHO for SCD is better conceptualized as a longitudinal clinical decision infrastructure analogous to regional tumor boards rather than as a training intervention aimed at clinician independence.
Methods
We conducted a comparative conceptual analysis of Project ECHO and multidisciplinary tumor boards as care-delivery models for rare and complex diseases. Key domains examined included decision-making structure, models of workforce development, expectations of clinician autonomy, reliance on multidisciplinary specialist input, mechanisms for guideline interpretation, and implications for sustainability and evaluation. Evidence sources included the original hepatitis C ECHO randomized trial and subsequent evaluations, established institutional and regional oncology tumor board practices, and structured comparison of workflows within SCD-focused ECHO programs involving primary care, emergency medicine, and hematology. This analysis focused on care-delivery structure and workforce sustainability rather than patient-level clinical outcomes.
Results
Project ECHO and multidisciplinary tumor boards shared core functional characteristics, including collective case deliberation, multidisciplinary expertise, longitudinal review of complex cases, and ongoing reliance on specialist input embedded in patient care. In neither model was transition to autonomous specialist practice an expected or measured outcome. In the hepatitis C ECHO randomized trial, clinical outcomes comparable to specialty care were achieved through continuous case-based mentorship with sustained specialist involvement, rather than autonomy-based workforce development. Tumor boards centralize expertise within institutions or regions, whereas Project ECHO distributes this function across geography, enabling community clinicians to participate meaningfully in guideline-concordant care while supported by a standing multidisciplinary specialty team through repeated, longitudinal case discussion. Within SCD-focused ECHO programs, sustained engagement, recurrent case presentations, and shared interpretation of guidelines—rather than “graduation” to independence—were the norm, closely paralleling regional tumor board models for rare cancers.
Conclusions
Reframing Project ECHO for SCD as a tumor-board–analogous clinical decision infrastructure shifts workforce development from a focus on individual clinician autonomy to the maintenance of durable systems of shared expertise. This perspective aligns with SCD guidelines and established approaches to rare disease care in oncology, where ongoing multidisciplinary case review is treated as essential components of standard care. Importantly, this framing clarifies Project ECHO’s core role as a distributed decision infrastructure. Evaluation frameworks should therefore prioritize sustained participation, recurrence of case discussion, geographic reach, cross-disciplinary engagement, and consistency with guideline-based decision-making rather than autonomy-based endpoints. In rare and complex diseases such as SCD, workforce sufficiency is achieved through shared systems of expertise rather than time-limited training interventions.